NCT02818517 Evaluation and Management of Cardio Toxicity in Oncologic Patients
| NCT ID | NCT02818517 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-08-01 |
| Primary Completion | 2030-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-08-01 with a primary completion date of 2030-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The survival rate of cancer patients has greatly increased over the past decades' mainly due to early detection and the use of new medications with higher doses and combined protocols. This achievement comes with the price of cardio toxicity, leading to cardiac dysfunction ranged from transient asymptomatic left ventricular dysfunction to cardiac death. In the long term, the risk of death from cardiovascular causes exceeds that of tumor recurrence for many types of cancer. As a result of the increasing number of long-term cancer survivors the magnitude of this problem is growing. Early identification of cardio toxicity can be identified by clinical follow-up and the use of electrocardiography, cardiac biomarkers (Troponin, brain natriuretic peptide) and echocardiogram. Past studies imply that the addition of angiotensin-converting-enzyme inhibitor (ACE inhibitor) and beta blockers to the patient's treatment may prevent the development of cardiac dysfunction. However, currently there are no specific or clear guidelines for the follow-up and management of cardio-toxicity in cancer patients. The aim of the study: To try to identify who are the patients at increased risk for developing cardio toxicity, by follow up of clinical evaluation, cardiac biomarkers and echocardiogram examination, in purpose of early diagnosis, management and prevention of cardiac events. For achieving this the investigators will build a registry which will include all the oncologic patients going an evaluation in the cardio-oncology clinic in the Tel Aviv Medical Center .
Eligibility Criteria
Inclusion Criteria: * All patient evaluated in the cardio-oncology clinic in Tel Aviv MC Exclusion Criteria: * In the prospective Study - patients not sign an informed consent form. Exclusion criteria experiment: Patient reluctance to continue the study.
Contact & Investigator
Udi Chorin, MD
PRINCIPAL INVESTIGATOR
Tel Aviv MC
Frequently Asked Questions
Who can join the NCT02818517 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02818517 currently recruiting?
Yes, NCT02818517 is actively recruiting participants. Contact the research team at michalpela@gmail.com for enrollment information.
Where is the NCT02818517 trial being conducted?
This trial is being conducted at Tel Aviv, Israel.
Who is sponsoring the NCT02818517 clinical trial?
NCT02818517 is sponsored by Tel-Aviv Sourasky Medical Center. The principal investigator is Udi Chorin, MD at Tel Aviv MC. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.